FULPHILA (Alphapharm Pty Ltd)
Product name
FULPHILA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
237 working days (255)
Active ingredients
pegfilgrastim
Registration type
New biosimilar medicine
Indication
FULPHILA (pre-filled syringe) is indicated for the treatment of cancer patients following chemotherapy, to decrease the duration of severe neutropenia and so reduce the incidence of infections, as manifested by febrile neutropenia.